Korsana Biosciences, Inc.
Korsana Biosciences, Inc. is a U.S.-based biotechnology company focused on discovering and developing novel therapies for neurodegenerative diseases. Its business centers on research-stage drug programs and related partnering, licensing, and asset transactions around its therapeutic candidates.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaResearch and development of drug candidates for neurodegenerative diseases.
Fees from options or licenses tied to specific therapeutic programs.
Sales of development materials or other program-related assets.
Tuotteet
Raportoitu · osuus liikevaihdosta- License Agreement87,5 %
- License12,5 %
Lähde: 10-K/A FY2024, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Korsana sells primarily to pharmaceutical and biotechnology counterparties that evaluate, license, or acquire rights to its therapeutic programs. It also transacts with development partners and strategic investors who fund or support specific drug assets. The end market is specialty life sciences, where buyers are focused on pipeline optionality, scientific data, and access to novel mechanisms in neurodegeneration.
Buy option or license rights to Korsana's therapeutic candidates for internal development.
Enter partnering or asset transactions tied to specific research programs and data packages.
Provide capital through financing transactions linked to corporate development or merger activity.
Strategia
Korsana’s strategy is to advance neuroscience drug candidates while using partnering, licensing, and asset transactions to support development. The company also relies on external financing and strategic transactions to fund its pipeline and extend operating runway. This model makes scientific progress and deal execution central to value creation.
Clinical and preclinical progress is the core driver of biotech value.
Non-dilutive deal flow can fund research and validate assets.
Research-stage companies typically need financing to sustain operations.
Maantiede
Korsana is based in the United States and operates as a U.S. biotechnology company. The available disclosures do not break out revenue by geography, and the company’s commercial activity appears tied to U.S.-based corporate, financing, and partnering transactions. Its exposure is therefore driven more by U.S. capital markets and regulatory oversight than by international sales diversification.
Riskit
Korsana faces classic early-stage biotech risks tied to clinical development uncertainty, financing needs, and the ability to complete strategic transactions. The company also has specific execution risk around the proposed merger and related financing, which could affect funding access and business continuity. As with most pharmaceutical development companies, regulatory outcomes, scientific failure, and partner dependence can materially alter value.
- Insufficient capital to fund operationsVaikutus: KriittinenTodennäköisyys: Korkea
The business expects to need additional funding and has a limited operating runway.
Kohdistuu: Cash runway and dilution
- Failure to complete the proposed mergerVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company disclosed that delays or failure to complete the merger could materially affect results and stock price.
Kohdistuu: Corporate transaction and financing continuity
- Clinical and scientific development failureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Therapeutic candidates may not demonstrate the required safety or efficacy profile.
Kohdistuu: Pipeline programs
- Dependence on third-party counterpartiesVaikutus: KeskitasoTodennäköisyys: Korkea
Revenue from options, licenses, and asset sales depends on partner interest and timing.
Kohdistuu: Partnering and non-dilutive revenue
Kirjanpito
Harkinnanvaraiset erätRevenue depends on contract milestones, delivery, and reimbursement terms rather than recurring sales.
Vaikutus: Can create quarter-to-quarter revenue volatility
Research costs are expensed as incurred, so spend timing directly affects reported results.
Vaikutus: High operating loss visibility
Nonrefundable advance payments are deferred until goods or services are received.
Vaikutus: Affects balance sheet and near-term expense timing
Private-company financing and pre-funded warrants may require complex classification and valuation.
Vaikutus: Can affect equity, dilution, and fair value estimates
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Korro Bio, Inc.
KRRO · Pharmaceutical Preparations
Neurogene Inc.
NGNE · Pharmaceutical Preparations
Pasithea Therapeutics Corp.
KTTA · Pharmaceutical Preparations
ProMIS Neurosciences Inc.
PMN · Pharmaceutical Preparations
Prothena Corporation plc
PRTA · Pharmaceutical Preparations
Prothena Corp.
Serina Therapeutics, Inc.
SER · Pharmaceutical Preparations
Päivitetty: 28.9.2026